SUN BIOPHARMA INC (SNBP) financial statements (2021 and earlier)

Company profile

Business Address 712 VISTA BLVD #305
WACONIA, MN 55387
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,4491,40515243892516459
Cash and cash equivalents2,4491,40515243892516459
Receivables3613324203217331815
Prepaid expense2831101951187400
Deferred tax assets    (3) 
Other undisclosed current assets     212359
Total current assets:3,0931,8477678771,732391433
Noncurrent Assets
Property, plant and equipment     1319
Other noncurrent assets5151  76  
Other undisclosed noncurrent assets     380
Total noncurrent assets:5151  761699
TOTAL ASSETS:3,1441,8987678771,808407532
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9011,2803,7252,2421,1252255
Accounts payable5971,0641,1961,24558504
Accrued liabilities3042121,2548425052251
Employee-related liabilities  1,094    
Interest and dividends payable 418115535  
Debt1162861429425078
Deferred revenue and credits   1933
Other undisclosed current liabilities742644312,983 567567
Total current liabilities:1,7591,6304,1705,5191,375616664
Noncurrent Liabilities
Long-term debt and lease obligation  286 3002 
Long-term debt, excluding current maturities  286 300  
Capital lease obligations    2 
Other undisclosed noncurrent liabilities    2,814 6
Total noncurrent liabilities:  286 3,11426
Total liabilities:1,7591,6304,4565,5194,489618670
Stockholders' equity
Stockholders' equity attributable to parent1,385268(3,689)(4,642)(2,681)(211)(138)
Preferred stock     200200
Common stock75432308686
Additional paid in capital42,33135,03825,62514,02910,94313,49213,458
Accumulated other comprehensive income (loss)305283(165)7613  
Accumulated deficit(41,258)(35,058)(29,153)(18,779)(13,667)(13,989)(13,882)
Total stockholders' equity:1,385268(3,689)(4,642)(2,681)(211)(138)
TOTAL LIABILITIES AND EQUITY:3,1441,8987678771,808407532

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues     1,357974
Revenue, net   149300
Cost of revenue     (595)(558)
Cost of goods and services sold     (517)(308)
Gross profit:     762415
Operating expenses(4,322)(3,891)(6,016)(5,168)(5,444)(665)(610)
Other undisclosed operating loss     (172) 
Operating loss:(4,322)(3,891)(6,016)(5,168)(5,444)(75)(194)
Nonoperating expense(2,293)(2,268)(4,894)(285)(239)  
Other nonoperating income (expense)(99)(508)255(107)(64)  
Interest and debt expense(2,194)(1,814)(3,696)(180)(183)(36)(36)
Other undisclosed income from continuing operations before equity method investments, income taxes2,1941,8143,696180183  
Loss from continuing operations before income taxes:(6,615)(6,159)(10,910)(5,453)(5,683)(111)(230)
Income tax expense (benefit)415254536341756(0)(0)
Other undisclosed income from continuing operations     419
Net loss:(6,200)(5,905)(10,374)(5,112)(4,927)(107)(212)
Other undisclosed net loss attributable to parent     (0)(0)
Net loss available to common stockholders, diluted:(6,200)(5,905)(10,374)(5,112)(4,927)(107)(212)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(6,200)(5,905)(10,374)(5,112)(4,927)(107)(212)
Comprehensive loss:(6,200)(5,905)(10,374)(5,112)(4,927)(107)(212)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent22448(241)6330  
Comprehensive loss, net of tax, attributable to parent:(6,178)(5,457)(10,615)(5,049)(4,897)(107)(212)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: